Background/Objective: Status epilepticus (SE) is a life-threatening condition with a high long-term mortality. The correct prediction of the individual patient's outcome is crucial for stratifying treatment. Status epilepticus severity score (STESS) and the epidemiology-based mortality score (EMSE) are well established for predicting in-hospital mortality; however, scores indicating long-term mortality are lacking. We here studied the association of both scores with mortality after discharge and long-term mortality.
Introduction
Status epilepticus (SE) is a frequent neurological condition with short-term mortality of 7.6-22% [1, 2] . Identification of patients with high mortality risk may allow better stratification of intensive treatment. Conversely, patients with low risk may not need admission to, or prolonged stay in, intensive care units (ICU) given the potential harms of treatment with anesthetics in the ICU [3, 4] . Several clinical scores aiming at predicting outcome after SE have been developed in recent years. The status epilepticus severity score (STESS) was the first test developed. It was designed to identify patients with good outcome before treatment initiation and was based on known prognostic factors [5, 6] . STESS includes 4 variables: Level of consciousness, worst seizure type, age, and history of previous seizures. In the original publication, STESS with a cutoff of ≥ 3 achieved the highest accuracy [5] . However, later studies suggested that a cutoff of ≥ 4 has a more favorable sensitivity and specificity [7] [8] [9] .
In 2015, Leitinger et al. published the epidemiologybased mortality score in status epilepticus (EMSE) that was developed based on epidemiological data. EMSE combines three (etiology, age, comorbidity-EAC) or four (etiology, age, comorbidity, and electroencephalography-EACE) factors to predict outcome. In this study, EMSE-EACE with a cutoff of ≥ 64 (for non-survivors) yielded best results and was also used in confirmatory cohorts [10] [11] [12] [13] . In addition, other scores have been proposed. The mSTESS combines the pre-morbid condition (modified Rankin Scale) with the STESS [14] . The EndIT score includes imaging results to estimate prognosis [15] . The usability of both, STESS and EMSE, has been confirmed multiple times, and both scores allowed robust evaluation of in-hospital mortality [5, 8, 10, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Others and we could show that mortality 2-3 years after discharge substantially exceeds in-house mortality [8, [22] [23] [24] [25] [26] . In a retrospective cohort study, more than 50% of the patients died within 3 years after diagnosis. STESS and its components and acute etiology alone were insufficient to explain or predict the high long-term mortality [8] . EMSE-EACE may allow a more precise prediction of long-term mortality, as it comprises three completely different prognostic factors. Therefore, we here studied, whether EMSE-EACE allowed correct prediction of long-term mortality after SE.
Methods

Patient Cohort
A total of 129 adult patients, with first-time, non-anoxic SE from the University Hospital of Odense (from January 2008 to December 2014), were retrospectively identified based on ICD-10 codes at discharge (G41X, n = 107) or documented SE in the electroencephalography (EEG)/ patient records (n = 22) as described in [26] . The diagnosis of clinical SE as defined in [1] was confirmed in all patients or if EEG showed SE without predominant motor symptoms ("non-convulsive SE") as evaluated by a senior neurophysiologist. The study was approved by the local and national authorities for data security (Sundhedsstyrelsen, 3-3013-696/1) and evaluated by the local ethic committee.
Data Assessment
For all patients, complete data on etiology, treatment, history of previous seizures, age, level of consciousness, type of SE (incl. seizure type), date of diagnosis, date of discharge, and date of death were available in the patients' journal. Comorbidities (Charlson comorbidity index [27] ) and all other parameters were retrospectively assessed from the patients' journal, whenever available. EEG was classified based on the detailed EEG description available in the electronic patients' journals. The patients' survival was last assessed at "end-of-study, " which was defined as survival status at last data evaluation in the electronic patient journals. All patients were treated according to international guidelines with benzodiazepine treatment as first-line treatment and phenytoin, valproic acid, or levetiracetam as second-line treatment. Propofol and midazolam were the preferred anesthetics used for narcosis [1] . As in other studies, refractory SE was defined as failure of first-and second-line treatment [14, 15, 17, [28] [29] [30] . 
Statistics
Results
Patients' Characteristics
A total of 129 adult patients with incident, first-time status epilepticus were analyzed in this study; 19.4% had an acute symptomatic cause or suffered from progressive brain disease (one patient with Lewy body disease, all others suffered from malignant brain tumors) as defined in the Guidelines for Epidemiologic Studies on Epilepsy [31] . EEG showed SE with or without predominant motor symptoms in 78% of all patients. Further details on the patients' characteristics and treatment are given in Table 1 and in Supplementary Table 1 .
Sensitivity and Specificity of STESS4 and EMSE-EACE
Using ROC analyses, we compared the sensitivity and specificity of EMSE-EACE and STESS for patients' mortality at discharge, at 3 months and at end-of-study (Fig. 1a-c) . Sensitivity and specificity of EMSE-EACE and STESS for mortality at discharge and 3 month after discharge did not differ (at discharge: area under the curve [AUC] 0.772 vs. 0.735; at 3 months: AUC 0.714 vs. 0.722). When looking at overall mortality at end-of-study, sensitivity and specificity of STESS for mortality were slightly inferior to EMSE-EACE with respect to sensitivity and specificity (AUC 0.663 vs. 0.718, Fig. 1c) . In patients that survived the acute phase of SE and were discharged alive from hospital, sensitivity and specificity of EMSE-EACE and STESS (at diagnosis) for survival after discharge were low for both scores with only borderline significance for STESS (AUC 0.666 vs. 0.617, Fig. 1d ).
STESS4 versus EMSE-EACE64 at Diagnosis and Long-Term Mortality
STESS with a cutoff between 4 and 5 did not allow predicting overall mortality (Chi-square 2.4, p = 0.1, logrank test, data not shown). When using a cutoff between 3 and 4 (Chi-square value 7.7, p = 0.005, log-rank test) or between 2 and 3 (Chi-square value 12.8, log-rank test, p < 0.001), STESS reached statistical significance for overall survival (Fig. 2a,b) . EMSE-EACE with a cutoff of 64 showed the strongest association with survival with a Chi-square value of 31.4 (p < 0.001, log-rank test, Fig. 2c ). Patients with an EMSE-EACE ≥ 64 had an average survival of 20.8 months (95% confidence interval (CI) 13.1-28.5) as compared to patients with a favorable EMSE-EACE (59.9 months, 95% CI 50.1-69.7). The median survival for patients with EMSE-EACE above and below 64 was 6.4 and 35.8 months, respectively.
For patients with an EMSE-EACE ≥ 64, 19.6% were alive after 3 years as compared to 68% of patients with a favorable score. Of all patients with STESS ≥ 3, 37.8% were alive as compared to 62% of the patients with STESS of < 3. In the cohort of patients that were discharged alive from hospital, EMSE-EACE remained highly significantly associated with mortality, STESS with a cutoff between 2 and 3 showed a borderline significance (p = 0.04), and STESS with other cutoffs remained without statistical significance (Fig. 2d-f ). An analysis of known prognostic factors associated with in-hospital mortality confirmed the prognostic relevance of STESS and EMSE components (supplementary Table 2 ).
Contributing Components of EMSE-EACE to In-Hospital Mortality and Mortality after Discharge
In an exploratory analysis aiming at the identification of components of EMSE-EACE associated with long-term mortality, we used ROC analysis of all four components of the EMSE-EACE score. At discharge, etiology was the crucial components with an AUC of 0.824 (Fig. 3a) . Scores for age and EEG alone did not reach statistical significance. When looking at patients who were discharged alive from hospital, age and comorbidity but not etiology and EEG were associated with survival after discharge (Fig. 3b) .
Discussion
We here show that EMSE-EACE at diagnosis is associated with both in-hospital mortality and mortality after discharge. The sensitivity and specificity of STESS and EMSE-EACE did not differ between in-hospital mortality and 3 months survival. However, STESS did hardly correlate with survival after discharge as shown in the KaplanMeier analyses. Both scores were not designed to predict long-term survival but were optimized for the prediction of in-hospital mortality [6, 10] . The lower sensitivity and specificity for prediction of mortality after discharge do not argue against the scores but reflect the original design.
Our data showing a significant association of EMSE-EACE with survival after discharge add, however, useful clinical information on long-term outcome that may help the clinician with the often difficult clinical decisions associated with SE treatment intensity.
Notably, the differences in sensitivity and specificity were less impressive as compared to the Kaplan-Meier analyses, which is due to the fact that ROC analyses considers "mortality at any time point, " while KaplanMeier analyses also take survivors and time-to-death into account.
In this study, we provide data illustrating the importance of comorbidities and age not only for acute mortality [16, 32, 33] but also for long-term outcome after SE. This association is not surprising, giving that both factors would also show associations with long-term mortality in any cohort with a mean age of 65 years [27] . The differences between STESS and EMSE-EACE are likely due to the different clinical parameters included in the scores. Fig. 1 Sensitivity and specificity of STESS and EMSE-EACE. a-c ROC analyses of sensitivity and specificity of STESS and EMSE-EACE for (a) in-house mortality (b), mortality 3 months after diagnosis, and (c) at end-of-study. d ROC analysis of sensitivity and specificity of mortality after discharge of patients that survived acute treatment and were discharged alive from hospital On average, the comorbidity score contributed more than 30% to the total EMSE-EACE score (data not shown) but is not considered in STESS, which appears to be the crucial differences between both scores with respect to long-term outcome. Unfortunately, we did not have sufficient data available to determine mSTESS (i.e., modified Rankin Score before admission) that was recently proposed by Gonzalez-Cuevas et al. [14] . However, one might speculate mSTESS might have been superior to STESS with respect to overall survival.
This study has limitations. Although this cohort has 100% follow-up due to the linkage of the electronic patient system and the Danish Civil Registry, we did not have information on the clinical status and treatment after discharge besides the date of death. Neither cause of death nor clinical/neurological status at death were known. Thus, we cannot exclude that the association of age and comorbidities and mortality after discharge might reflect, to a certain degree, a more passive treatment approach of treating physicians, in patients with substantial comorbidities, high age, and former SE. Further, our cohort was not population-based and might have a slight bias toward more severely ill patients. However, given that STESS and EMSE are hardly ever used for patients with benzodiazepine-responsive SE, we do not think that these issues impact the overall message of our paper. Analysis of risk factors for mortality after discharge. a ROC analysis of the four different components of EMSE-EACE with respect to sensitivity and specificity for mortality at discharge. b ROC analysis of the four different components of EMSE-EACE with respect to sensitivity and specificity for mortality at end-of-study in patients that were discharged alive from the hospital
